Genetic determinants of cardiovascular disease: The renin-angiotensin- aldosterone system, paraoxonases, endothelin-1, nitric oxide synthase and adrenergic receptors

In Vivo

Volumn 23, Issue 5, 2009, Pages 797-812

  Gluba, Anna ^a   Banach, Maciej ^a   Mikhailidis, Dimitri P ^b   Rysz, Jacek ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Cardiovascular diseases; Genetic determinants; Predictors; Review; Risk stratification

Indexed keywords

ADRENERGIC RECEPTOR; ARYLDIALKYLPHOSPHATASE; ENDOTHELIN 1; NITRIC OXIDE SYNTHASE;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE COURSE; FAMILY HISTORY; GENETIC RISK; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMOBILIZATION; METABOLIC SYNDROME X; OBESITY; PROGNOSIS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW;

EID: 70350064389     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (233)

1. Kowalski J, Barylski M, Banach M, Grycewicz J, Irzmański R and Pawlicki L: Neutrophil superoxide anion generation during atorvastatin and fluvastatin therapy used in coronary heart disease primary prevention. J Cardiovasc Pharmacol 48: 143-147, 2006. (Pubitemid 44691215)
2. Boncler M, Gresner P, Nocun M, Rywaniak J, Dolnik M, Rysz J, Wilk R, Czyz M, Markuszewski L, Banach M and Watala C: Elevated cholesterol reduces acetylsalicylic acid-mediated platelet acetylation. Biochim Biophys Acta 1770: 1651-1659, 2007. (Pubitemid 47633819)
3. McAllister HA Jr., Hall RJ and Cooley DA: Tumors of the heart and pericardium. Curr Probl Cardiol 24: 57-116, 1999.
4. Masajtis A, Barylski M, Banach M, Rysz J and Drożḋ J: Zawał miȩśnia sercowego - narastaja̧cy problem u młodych osób. Przew Lek 2: 74-79, 2006.
5. Choudhury L and Marsh J: Myocardial infarction in young patients. Am J Med 107: 254-261, 1999.
6. Klein LW, Agarwal JB, Herlich MB, Leary TM and Helfant RH: Prognosis of symptomatic coronary artery disease in young adults aged 40 years or less. Am J Cardiol 60: 1269-1272, 1987.
7. Petronio AS, Baglini R, Limbruno U, Mengozzi G, Amoroso G, Cantarelli A, Vaghetti M, Distante A, Balbarini A and Mariani M: Coronary collateral circulation behaviour and myocardial viability in chronic total occlusion treated with coronary angioplasty. Eur Heart J 19: 1681-1687, 1998. (Pubitemid 28524187)
8. Banach M, Rysz J, Goch A, Mikhailidis DP and Rosano GM: The role of trimetazidine after acute myocardial infarction. Curr Vasc Pharmacol 6: 282-291, 2008.
9. Kraus WE: Genetic approaches for the investigation of genes associated with coronary heart disease. Am Heart J 140: S27-S35, 2000.
10. Chaer RA, Billeh R and Massad MG: Genetics and gene manipulation therapy of premature coronary artery disease. Cardiology 101: 122-130, 2004. (Pubitemid 38339714)
11. O'Donnell CJ: Family history, subclinical atherosclerosis, and coronary heart disease risk barriers and opportunities for the use of family history information in risk prediction and prevention. Circulation 110: 2074-2076, 2004.
12. Williams RR, Hunt SC, Heiss G, Province MA, Bensen JT, Higgins M, Chamberlain RM, Ware J and Hopkins PN: Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study). Am J Cardiol 87: 129-135, 2001. (Pubitemid 32057219)
13. Kowalski J, Banach M, Barylski M, Irzmanski R and Pawlicki L: Carvedilol modifies antioxidant status of patients with stable angina. Cell Mol Biol Lett 13: 230-239, 2008.
14. Marenberg ME, Risch N, Berkman LF, Floderus B and de Faire U: Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med 330: 1041-1046, 1994. (Pubitemid 24106561)
15. Nasir K, Michos ED, Rumberger JA, Braunstein JB, Wendy S, Post WS, Matthew J, Budoff MJ and Blumenthal RS: Coronary artery calcification and family history of premature coronary heart disease: sibling history is more strongly associated than parental history. Circulation 110: 2150-2156, 2004 (Pubitemid 39372493)
16. Piestrzeniewicz K, Łuczak K, Maciejewski M and Goch JH: Impact of obesity and adipokines on cardiac structure and function in men with first myocardial infarction. Arch Med Sci 4: 152-160, 2008.
17. Wojtczak A and Skrȩtkowicz J: Genetics in ischaemic heart disease. Pol Merk Lek 23: 133-135, 2007.
18. Hanatani A, Yoshiyama M, Kim S, Omura T, Toda I, Akioka K, Teragaki M, Takeuchi K, Iwao H and Takeda T: Inhibition by angiotensin II type I receptor antagonist of cardiac phenotypic modulation after myocardial infarction. J Mol Cell Cardiol 27: 1905-1914, 1995.
19. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT: Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 67: 1355-1364, 1990.
20. Urata H, Boehm KD, Philip A, Kinoshita A, Gabrovsek J, Bumpus FM and Husain A: Cellular localization and regional distribution of an angiotensin II forming chymase in the heart. J Clin Invest 91: 1269-1281, 1993. (Pubitemid 23127321)
21. Tsai CT, Lai LP, Lin JL, Chiang FT, Hwang JJ, Ritchie MD, Moore JH, Hsu KL, Tseng CD, Liau CS and Tseng YZ: Renin-angiotensin system gene polymorphisms and atrial fibrillation. Circulation 109: 1640-1646, 2004.
22. Weber KT, Brilla CG, Janicki JS: Myocardial fibrosis: functional significance and regulatory factors. Cardiovasc Res 27: 341-348, 1993.
23. von Depka M, Czwalinna A, Wermes C, Eisert R, Scharrer I, Ganser A and Ehrenforth S: The deletion polymorphism in the angiotensin-converting enzyme gene is a moderate risk factor for venous thromboembolism. Thromb Haemost 89: 847-852, 2003. (Pubitemid 36603428)
24. Ridker PM, Gaboury CL, Conlin PR, Seely EW, Williams GH and Vaughan DE: Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II: evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 87: 1969-1973, 1993.
25. Vaughan DE, Lazos SA and Tonk K: Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells: a potential link between the renin-angiotensin system and thrombosis. J Clin Invest 95: 995-1001, 1995.
26. Soubrier F, Wei L, Hubert C, Clauser E, Alhenc-Gelas F and Corvol P: Molecular biology of the angiotensin I-converting enzyme: part II. Structure-function. Gene polymorphism and clinical implications. J Hypert 11: 599-604, 1993. (Pubitemid 23225202)
27. Kowalczyk E, Kopff M, Kowalski J, Kopff A, Mikhailidis DP, Barylski M and Banach M: Effect of cardiovascular drugs on adenosine deaminase activity. Angiology 59: 740-744, 2009.
28. Krege JH, John SWM, Langenbach LL, Hodgin JB, Hagaman JR, Bachman ES, Jennette JC, O'Brien DA and Smithies O. Male-female differences in fertility and blood pressure in ACE-deficient mice. Nature 375: 146-148, 1995.
29. Yusuf S, Pepine CJ, Garces C, Pouleur H, Salem D, Kostis J, Benedict C, Rousseau M, Bourassa M and Pitt B: Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fraction. Lancet 340: 1173-1178, 1992.
30. Pfeffer MA, Braunwald E, Moyé LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR, Geltman EM, Goldman S and Flaker GC: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction - results of the survival and ventricular enlargement trial. N Engl J Med 327: 669-677, 1992.
31. O'Driscoll G, Green D and Rankin J: Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J Clin Invest 100: 678-684, 1997. (Pubitemid 27340517)
32. Rigat B, Hubert C, Corvol P and Soubrier F: PCR detection of the insertion/deletion polymorphism of the human angiotensin I converting enzyme gene (DCPI). Nucleic Acids Res 20: 1433, 1992.
33. Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F and Soubrier F: Evidence from combined segregation and linkage analysis that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE. Am J Hum Genet 51: 197-205, 1992.
34. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P and Soubrier F: An insertion/deletion polymorphism in the angiotensin I converting gene accounting for half the variance of serum enzyme levels. J Clin Invest 86: 1343-1346, 1990. (Pubitemid 20370444)
35. Tokunaga S, Tsuji H, Nishiue T, Yamada K, Miysaka Y, Saitou D and Iwasaka T: Lower mortality in patients with the DD genotype of the angiotensin- converting enzyme gene after acute myocardial infarction. Acta Cardiol 56: 351-355, 2001. (Pubitemid 34885114)
36. Cambien F, Poirier O, Lecerf L, Evans A, Cambou JP, Arveiler D, Luc G, Bard JM, Bara L, Ricard S, Tiret L, Amouyel P, Alhenc-Gelas P and Soubrier F: Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 359: 641-644, 1992.
37. Samani NJ, Thompson JR, O'Toole L, Channer K and Woods KL: A meta-analysis of the association of the deletion allele of the angiotensin-converting enzyme gene with myocardial infarction. Circulation 94: 708-712, 1996. (Pubitemid 26289226)
38. Ludwig EH, Cornell PS, Anderson JL, Marshall HW, Lalouel JM and Ward RH: Angiotensin-converting enzyme gene polymorphism is associated with myocardial infarction but not with development of coronary stenosis. Circulation 91: 2120-2124, 1995.
39. Nakai K, Itoh C, Miura Y, Hotta K, Musha T, Itoh T, Miyakawa T, Iwasaki R and Hiramori K: Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with serum ACE concentration and increased risk for CAD in the Japanese. Circulation 90: 2199-2202, 1994. (Pubitemid 24354301)
40. Agerholm-Larsen B, Nordestgaard BG, Tybjaerg-Hansen A: ACE gene polymorphism in cardiovascular disease. Meta-analysis of small and large studies in whites. Arterioscler Thromb Vasc Biol 20: 484-492, 2000.
41. van Geel PP, Pinto YM, Zwinderman AH, Henning RH, Van Boven AJ, Jukema J.W, Bruschke A, Kastelein J, van Gilst WH, and G Baxter: Increased risk for ischaemic events is related to combined RAS polymorphism. Heart 85: 458-462, 2001. (Pubitemid 32973539)
42. Raynolds MV, Bristow MR, Bush EW, Abraham WT, Lowes BD, Zisman LS, Taft CS, and Perryman MB: Angiotensin-converting enzyme DD genotype in patients with ischemic or idiopathic dilated cardiomyopathy. Lancet 342: 1073-1075, 1993. (Pubitemid 23338738)
43. Ohmichi N, Iwai N, Maeda K, Shimoike H, Nakamuray Y, Izumi M, Sugimoto Y and Kinoshita M: Genetic basis of left ventricular remodeling after myocardial infarction. Int J Cardiol 53: 265-272, 1996. (Pubitemid 26178159)
44. Castellano M, Muiesan ML, Rizzoni D, Pasini G, Cinelli A, Salvetti M, Porteri E, Bettoni G, Kreutz R, Lindpaintner K and Rosei EA: Angiotensin-converting enzyme I/D polymorphism and arterial wall thickness in a general population: the Vobarno study. Circulation 91: 2721-2724, 1995.
45. Amant C, Bauters C, Bodart J-C, Lablanche J-M, Grollier G, Danchin N, Hamon M, Richard F, Helbecque N, McFadden EP, Amouyel P and Bertrand ME: D allele of the angiotensin I-converting enzyme is a major risk factor for restenosis after coronary stenting. Circulation 96: 56-60, 1997. (Pubitemid 27298404)
46. Samani NJ, Martin DS, Brack M, Cullen J, Chauhan A, Lodwick D, Harley A, Swales JD, de Bono DP and Gershlicka AH: Insertion/deletion polymorphism in the angiotensin-converting enzyme gene and risk of restenosis after coronary angioplasty. Lancet 345: 1013-1016, 1995.
47. Kane JP, Malloy MJ, Ports TA, Phillips NR, Diehl JC and Havel RJ: Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens. JAMA 264: 3007-3012, 1990.
48. Daeman MJP, Lombardi DM, Bosman FT and Schwartz SM: Angiotensin II induces smooth muscle proliferation in the normal and injured rat arterial wall. Circ Res 68: 450-456, 1991.
49. O'Malley JP, Maslen CL and Illingworth DR: Angiotensin-converting enzyme DD genotype and cardiovascular disease in heterozygous familial hypercholesterolemia. Circulation 97: 1780-1783, 1998.
50. Ohmichi N, Iwai N, Nakamura Y and Kinoshita M: The genotype of the angiotensin-converting enzyme gene and global left ventricular dysfunction after myocardial infarction. Am J Cardiol 76: 326-329, 1995.
51. McNamara DM, Holubkov R, Janosko K, Palmer A, Wang JJ, MacGowan G.A, Murali S, Rosenblum WD, London B and Feldman AM: Pharmacogenetic interactions between β-blocker therapy and the angiotensin-converting enzyme deletion polymorphism in patients with congestive heart failure. Circulation 103: 1644-1648, 2001. (Pubitemid 32246611)
52. Reid IA, Morris BJ and Ganong WJ: The renin-angiotensin system. Annu Rev Physiol 40: 377-410, 1978.
53. Nguyen DC, Hamaguchi K, Saikawa T, Hara M and Sakata T: A polymorphism of angiotensinogen gene codon 174 and coronary artery disease in Japanese subjects. (Abstract). Am J Med Sci 316: 289-328, 1998.
54. Gardemann A, Stricker J, Humme J, Nguyen QD, Katz N, Philipp M, Tillmanns H, Hehrlein FW and Haberbosch W: Angiotensinogen T174M and M235T gene polymorphisms are associated with the extent of coronary atherosclerosis. Atherosclerosis 145: 433-436, 1999.
55. Kunz R, Kreutz R, Beige J, Distler A and Sharma AM: Association between the angiotensinogen 235T-variant and essential hypertension in whites: a systematic review and methodological appraisal. Hypertension 30: 1331-1337, 1997. (Pubitemid 27528071)
56. Ko YL, Ko YS, Wang SM, Chu PH, Teng MS, Cheng NJ, Chen WJ, Hsu TS, Kuo CT, Chiang CW and Lee YS: Angiotensinogen and angiotensin-I converting enzyme gene polymorphisms and the risk of coronary artery disease in Chinese. Hum Genet 100: 210-214, 1997. (Pubitemid 27338792)
57. Gould AB: Kinetics of the human renin and human substrate reaction. Cardiovasc Res 5: 86-89, 1971.
58. Ishigami T, Umemura S, Iwamoto T, Tamura K, Hibi K, Yamaguchi S, Nyuui N, Kimura K, Miyazaki N and Ishii M: Molecular variant of angiotensinogen gene is associated with coronary atherosclerosis. Circulation 91: 951-954, 1995.
59. Lanz JR, Pereira AC, Lemos PA, Martinez E and Krieger JE: Angiotensinogen M235T polymorphism is associated with coronary artery disease severity. Clin Chim Acta 362: 176-181, 2005. (Pubitemid 41597103)
60. Tsai CT, Hwang JJ, Lai LP, Wang YC, Lin JL and Chiang FT: Interaction of gender, hypertension, and the angiotensinogen gene haplotypes on the risk of coronary artery disease in a large angiographic cohort. Atherosclerosis 203: 249-256, 2009.
61. Sato N, Katsuya T, Nakagawa T, Ishikawa K, Fu Y, Asai T, Fukuda M, Suzuki F, Nakamura Y, Higaki J and Ogihara T: Nine polymorphisms of angiotensinogen gene in the susceptibility to essential hypertension. Life Sci 68: 259-272, 2000.
62. Davis D, Liyou N, Lockwood D and Johnson A: Angiotensinogen genotype, plasma protein and mRNA concentration in isolated systolic hypertension. Clin Genet 61: 363-368, 2002. (Pubitemid 36372667)
63. Inuoe I, Nakajima T, Williams CS, Quackenbush J, Puryear R, Powers M, Cheng T, Ludwig EH, Sharma AM, Hata A, Jeunemaitre X and Lalouel JM: A nucleotide substitution in the promoter of human angiotensinogen is associated with essential hypertension and affects basal transcription in vitro. J Clin Invest 99: 1786-1797, 1997. (Pubitemid 27164639)
64. Staessen JA, Kuznetsova T, Wang JG, Emelianov D, Vlietinck R and Fagard R: M235T angiotensinogen gene polymorphism and cardiovascular renal risk. J Hypertens 17: 9-17, 1999. (Pubitemid 29086182)
65. Azizi M, Hallouin MC, Jeunemaitre X, Guyene TT and Ménard J: Influence of the M235T polymorphism of human angiotensinogen (AGT) on plasma AGT and renin concentrations after ethinylestradiol administration. J Clin Endocr Metab 85: 4331-4337, 2000. (Pubitemid 32055395)
66. Jeunemaitre X, Soubrier F, Kotelevtsev Y, Lifton R, Williams CS, Charru A, Hunt SC, Hopkins PN, Williams RR, Lalouel JM and Corvol P: Molecular basis of human hypertension: role of angiotensinogen. Cell 71: 169-180, 1992.
67. Sethi AA, Nordestgaard BG, Gronholdt ML, Steffensen R, Jensen G and Tybjærg-Hansen A: Angiotensinogen single nucleotide polymorphisms, elevated blood pressure, and risk of cardiovascular disease. Hypertension 41: 1202-1211, 2003. (Pubitemid 36706066)
68. Clauser E, Gaillard I, Wei L and Corvol P: Regulation of angiotensinogen gene. Am J Hypertens 2: 403-410, 1989.
69. Kisley LR, Sakai RR, Flanagan-Cato LM and Fluharty SJ: Estrogen increases angiotensin II-induced c-Fos expression in the vasopressinergic neurons of the paraventricular nucleus in the female rat. Neuroendocrinology 72: 306-317, 2000.
70. Buraczyńska M, Dzida G, Puźniak A, Sobstyl J and Hanzlik J: Association between angiotensinogen and atrial natriuretic peptide gene polymorphisms and increased risk of coronary heart disease. Kardiol Pol 53: 103-106, 2000 (in Polish).
71. Nickenig G and Harrison DG: The AT1-type angiotensin receptor in oxidative stress and atherogenesis, part I: oxidative stress and atherogenesis. Circulation 105: 393-396. 2002. (Pubitemid 34106191)
72. Ruiz-Ortega M, Esteban V and Egido J: The regulation of the inflammatory response through nuclear factor-κB pathway by angiotensin IV extends the role of the renin angiotensin system in cardiovascular diseases. (Abstract). Trends Cardiovasc Med 17: 19-25, 2007. (Pubitemid 46038768)
73. Ruiz-Ortega M, Lorenzo O, Esteban V, Suzuki Y, Mezzano S, Plaza JJ and Egido J: Role of the Renin-Angiotensin System in Vascular Diseases Expanding the Field. Hypertension 38: 1382-1387, 2001. (Pubitemid 34033420)
74. Weiss D, Sorescu D and Taylor WR: Angiotensin II and atherosclerosis. Am J Cardiol 87 suppl: 25C-32C, 2001.
75. Baudin B: Polymorphism in angiotensin II receptor genes and hypertension. Exp Physiol 90: 277-1182, 2005.
76. de Gasparo M, Catt KJ, Inagami T, Wright JW and Unger T: International Union of Pharmacology. XXIII. The angiotensin II receptors. Pharmacol Rev 52: 415-472, 2000.
77. Gräfe M, Graf K, Auch-Schwelk W, Hertel H, Hoffmann R, Bartsch P and Fleck E: Modulation of adhesion molecule expression in human coronary endothelial cells. Eur Heart J 14: 58-58, 1993 (abstract).
78. Hahn AWA, Jonas U, Buhler FR and Resink TJ: Activation of human peripheral monocytes by angiotensin II. FEBS Lett 347: 178-180, 1994.
79. Itoh H, Pratt RE, Gibbons G and Dzau VJ: Multiple autocrine growth factors mutate vascular smooth muscle cell growth response to angiotensin II. J Clin Invest 91: 2268-2274, 1993.
80. Diet F, Pratt RE, Berry GJ, Momose N, Gibbons GH and Dzau VJ: Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 94: 2756-2767, 1996. (Pubitemid 26411739)
81. Weinstock JV, Blum AM and Kassab JT: Angiotensin II is chemotactic for a T-cell subset which can express migration inhibition factor activity in murine schistosomiasis mansoni. Cell Immunol 107: 180-187, 1987.
82. Griendling KK, Minieri CA, Ollerenshaw JD and Alexander RW: Angiotensin II stimulates NADH and NADPH oxidase activation in cultured vascular smooth muscle cells. Circ Res 74: 1141-1148, 1994. (Pubitemid 24176909)
83. Yanagitani Y, Rakugi H, Okamura A, Moriguchi K, Takiuchi S and Ohishi M: Angiotensin II type 1 receptor-mediated peroxide production in human macrophages. Hypertension 33(1 Pt 2): 335-339, 1999. (Pubitemid 29065681)
84. Landmesser U and Drexler H: Oxidative stress, the reninangiotensin system, and atherosclerosis. Eur Heart J Suppl 5 suppl A: A3-A7, 2003. (Pubitemid 36134240)
85. Keidar S and Attias J: Angiotensin II injection into mice increases the uptake of oxidized LDL by their macrophages via a proteoglycan-mediated pathway. Biochem Biophys Res Commun 239: 63-67, 1997. (Pubitemid 27480316)
86. Schieffer E, Schieffer B, Hilfiker-Kleiner D, Hilfiker A, Kovanen PT, Kaartinen M, Nussberger J, Harringer W, Drexler H: Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: potential implications for inflammation and plaque instability. Circulation 101: 1372-1378, 2000. (Pubitemid 30169857)
87. Barylski M, Kowalczyk E, Banach M, Ciecwierz J, Pawlicki L and Kowalski J: Plasma total antioxidant activity in comparison with plasma NO and VEGF levels in patients with metabolic syndrome. Angiology 60: 87-92, 2009.
88. Griffin SA, Brown WC, MacPherson F, McGrath JC, Wilson VG, Korsgaard N, Mulvany MJ and Lever AF: Angiotensin II causes vascular hypertrophy in part by a non-pressor mechanism. Hypertension 17: 626-635, 1991.
89. Cox S, Ben A, Story DF and Ziogas J: Evidence for the involvement of different receptor subtypes in the pre- and postjunctional actions of angiotensin II at rat sympathetic neuroeffector sites. Br J Pharmacol 114: 1057-1063, 1995.
90. Dayuan L, Baichun Y, Philips MI and Mehta JL: Proapoptotic effects of ANG II in human coronary artery endothelial cells: role of AT1 receptor and PKC activation. Am J Physiol Heart Circ Physiol 45: H786-H792, 1999.
91. Diep QN, Li JS and Schiffrin EL: In vivo study of AT1 and AT2 angiotensin receptors in apoptosis in rat blood vessels. Hypertension 34: 617-624, 1999.
92. Sayer JW and Timmis AD: Angiotensin-converting enzyme inhibitors and coronary artery disease. Cardiovasc Drugs Therapy 10 suppl 2: 631-637, 1996. (Pubitemid 27010884)
93. Kurland L, Melhus H, Sarabi M, Millgard J, Ljunghall S and Lind L: Polymorphisms in the renin-angiotensin system and endothelium-dependent vasodilation in normotensive subjects. Clin Physiol 21: 343-349, 2001. (Pubitemid 32487591)
94. van Geel PP, Pinto YM, Voors AA, Buikema H, Oosterga M, Crijns HJGM and van Gilst WH: Angiotensin II type 1 receptor A1166C gene polymorphism is associated with an increased response to angiotensin II in human arteries. Hypertension 35: 717-721, 2000. (Pubitemid 30165315)
95. Bonnardeaux A, Davies E, Jeunemaitre X, Ferry I, Charru A, Clauser E, Tiret L, Cambien F, Corvol P and Soubrier F: Angiotensin II type 1 receptor gene polymorphism in human essential hypertension. Hypertension 24: 63-69, 1994. (Pubitemid 24195405)
96. Amant C, Hamon M, Bauters C, Richard F, Helbecque N, McFadden EP, Escudero X, Lablanche JM, Amouyel P and Bertrand ME: The angiotensin II type 1 receptor gene polymorphism is associated with coronary artery vasoconstriction. J Am Coll Cardiol 29: 486-490, 1997. (Pubitemid 27116087)
97. Osterop AP, Kofflard MJ, Sandkuijl LA, ten Cate FJ, Krams R, Schalekamp MA and Danser AH: AT1 receptor A/C 1166 polymorphism contributes to cardiac hypertrophy in subjects with hypertrophic cardiomyopathy. Hypertension 32: 825-830, 1998.
98. Wang WY, Zee RY and Morris BJ: Association of angiotensin II type 1 receptor gene polymorphism with essential hypertension. Clin Genet 51: 31-34, 1997. (Pubitemid 27116896)
99. Spiering W, Spiering W, Kroon AA, Fuss-Lejeune MMJJ, Daemen MJAP and de Leeuw PW: Angiotensin II sensitivity is associated with the angiotensin II type 1 receptor A(1166)C polymorphism in essential hypertensives on a high sodium diet. Hypertension 36: 411-416, 2000. (Pubitemid 30694798)
100. Tiret L, Bonnardeaux A, Poirier O, Ricard S, Marques-Vidal P, Evans A, Arveiler D, Luc G, Kee F and Ducimetière P: Synergistic effects of angiotensin-converting enzyme and angiotensin-II type 1 receptor gene polymorphisms on risk of myocardial infarction. Lancet 344: 910-913, 1994. (Pubitemid 24295876)
101. Diez J, Laviades C, Orbe J, Zalba G, Lopez B, Gonzalez A, Mayor G, Páramo JA and Beloqui O: The A1166C polymorphism of the AT1 receptor gene is associated with collagen type I synthesis and myocardial stiffness in hypertensives. Hypertension 21: 2085-2092, 2003. (Pubitemid 38296870)
102. Andersson B, Blange I and Sylven C: Angiotensin-II type 1 receptor gene polymorphism and long-term survival in patients with idiopathic congestive heart failure. Eur J Heart Fail 1: 363-369, 1999. (Pubitemid 30131044)
103. Hamon M, Amant C, Bauters C, Richard F, Helbecque N, McFadden EP, Lablanche JM, Bertrand M, and Amouyel P: Association of angiotensin-converting enzyme and angiotensin II type 1 receptor genotypes with left ventricular function and mass in patients with angiographically normal coronary arteries. Heart 77: 489-490, 1997.
104. Gruchala M, Ciecwierz D, Ochman K, Wasag B, Koprowski A, Wojtowicz A, Dubaniewicz W, Targonski R, Sobiczewski W, Grzybowski A, Grzybowski A, Romanowski P, Limon J and Rynkiewicz A: Left ventricular size, mass and function in relation to angiotensin-converting enzyme gene and angiotensin-II type 1 receptor gene polymorphisms in patients with coronary artery disease. Clin Chem Lab Med 41: 522-528, 2003. (Pubitemid 36592119)
105. Wolf G: The road not taken: role of angiotensin II type 2 receptor in pathophysiology. Nephrol Dial Transplant 17: 195-198, 2002. (Pubitemid 34157126)
106. Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R and Unger T: The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. J Clin Invest 95: 651-657, 1995.
107. Pucell AG, Hodges JC, Sen I, Bumpus FM and Husain A: Biochemical properties of the ovarian granulosa cell type 2-angiotensin II receptor. Endocrinology 128: 1947-1959, 1991 (abstract).
108. Dudley DT and Summerfelt RM: Regulated expression of angiotensin II (AT2) binding sites in R3T3 cells. Regul Pept 44: 199-206, 1993. (Pubitemid 23083367)
109. Ouali R, Berthelon MC, Bégeot M and Saez JM: Angiotensin II receptor subtypes AT1 and AT2 are down-regulated by angiotensin II through AT1 receptor by different mechanisms. Endocrinology 138: 725-733, 1997. (Pubitemid 27110925)
110. Williams GH, Moore TJ and Hollenberg NK: Dysregulation of aldosterone secretion and its relationship to the pathogenesis of essential hypertension. Endocrinol Metab Clin North America 20: 423-447, 1991.
111. Refaat S, El-Ghaffar NA, El-Rahman Negm HA and Yousri T: The role of aldosterone in myocardial dysfunction of Egyptian patients with essential hypertension. Arch Med Sci 4: 161-166, 2008.
112. Cohn JN and Colucci W: Cardiovascular effects of aldosterone and post-acute myocardial infarction pathophysiology. Am Cardiol 97: 4-12, 2006. (Pubitemid 43673930)
113. Donderski R, Grajewska M and Manitius J: Aldosteron i jego znaczenie w uszkodzeniu układu sercowo-naczyniowego u osób z przewlekła̧ choroba̧ nerek. Kardiol Pol 64: 423-427, 2006.
114. Schiffrin EL: Wpływ aldosteronu na naczynia. Hypertension (Polish edition) 2: 1-7, 2006.
115. Hyla-Klekot L, Pulcer B and Kokot F: Układ renina-angiotensyna- aldosteron- nowe aspekty patogenetyczne i lecznicze. Czȩść 2. Aldosteron - ważny induktor szlaków patogenetycznych uszkadzaja̧cych układ sercowo-naczyniowy i nerki. Nadcisn Tȩtn 11: 357-363, 2007.
116. Sutton MG and Sharpe N: Left ventricular remodeling after myocardial infarction pathophysiology and therapy. Circulation 101: 2981-2988, 2000. (Pubitemid 30415891)
117. Ahokas RA, Warrington KJ, Gerling IC, Sun Y, Wodi LA, Herring P, Lu L, Bhattacharya SK, Postlethwaite AE and Weber KT: Aldosteronism and peripheral blood mononuclear cell activation: a neuroendocrine-immune interface. Circ Res 93: e124-e135, 2003.
118. Marumo T, Uchimura H, Hayashi M, Hishikawa K and Fujita T: Aldosterone impairs bone marrow-derived progenitor cell formation. Hypertension 48: 490-496, 2006. (Pubitemid 44253745)
119. Kara-Perz, Kosicka T, Ghiszek J: Rola aldosteronu i antagonistów receptorów aldosteronu w chorobach układu sercowo-naczyniowego. Przewodnik Lekarza 7: 98-102, 2004.
120. Ouvrard-Pascaud A, Sainte-Marie Y, Bénitah JP, Perrier R, Soukaseum C, Cat AN, Royer A, Le Quang K, Charpentier F, Demolombe S, Mechta-Grigoriou F, Beggah AT, Maison-Blanche P, Oblin ME, Delcayre C, Fishman GI, Farman N, Escoubet B and Jaisser F: Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias. Circulation 111: 3025-3033, 2005. (Pubitemid 40847778)
121. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ, Funder JW and McMahon EG: Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 93: 69-76, 2003. (Pubitemid 36859043)
122. Biondi-Zoccai GG, Abbate A and Baldi A: Potential antiapoptotic activity of aldosterone antagonists in postinfarction remodeling [letter]. Circulation 108: e26, 2003.
123. Kupari M, Hautanen A, Lankinen I, Koskinen P, Virolainen J, Nikkila H and White PC: Associations between human aldosterone synthase (CYP11B2) gene polymorphisms and left ventricular size, mass, and function. Circulation 97: 569-575, 1998. (Pubitemid 28090686)
124. White PC and Slutsker L: Haplotype analysis of CYP11B2. Endocr Res 21: 437-442, 1995.
125. Davies E, Holloway CD, Ingram MC, Inglis GC, Friel EC, Morrison C, Anderson NH, Fraser R and Connell JMC: Aldosterone excretion rate and blood pressure in essential hypertension are related to polymorphic differences in the aldosterone synthase gene CYP11B2. Hypertension 33: 703-707, 1999. (Pubitemid 29091652)
126. Lala DS, Rice DA and Parker KL: Steroidogenic factor I, a key regulator of steroidogenic enzyme expression, is the mouse homolog of fushi tarazu-factor I. Mol Endocrinol 6: 1249-1258, 1992.
127. Tamaki S, Iwai N, Tsujita Y and Kinoshita M: Genetic polymorphism of CYP11B2 gene and hypertension in Japanese. Hypertension 33: 266-270, 1999. (Pubitemid 29065670)
128. Klimov AN, Gurevich VS, Nikiforova AA, Shatilina LV, Kuzmin AA, Plavinsky SL and Teryukova NP: Antioxidative activity of high density lipoprotein in vivo. Atheriosclerosis 100: 13-18, 1993. (Pubitemid 23166004)
129. Kelso GJ, Stuart WD, Richter RJ, Furlong CE, Jordan-Starck TC and Harmony AK: Apolipoprotein J is associated with paraoxonase in human plasma. Biochemistry 33: 832-839, 1994.
130. Filippatos TD, Tsimihodimos V, Kostapanos M, Kostara C, Bairaktari ET, Kiortsis DN, Tselepis AD and Elisaf MS: Small dense LDL cholesterol and apolipoproteins C-II and C-III in non-diabetic obese subjects with metabolic syndrome. Arch Med Sci 4: 263-269, 2008.
131. Primo-Parmo SL, Hsu C, Law DJ, La Du BN: Location and arrangement of three paraoxonase genes: PON1, PON2 and PON3, on human chromosome 7. Am J Hum Genet suppl 59: A406, 1996.
132. Guxens M, Tomas M, Elosua R, Aldasoro E, Segura A, Fiol M, Sala J, Vila J, Fullana M, Sentí M, Vega G, de la Rica M, Marrugat J and investigadores del estudio IBERICA: Association between paraoxonase-1 and paraoxonase-2 polymorphisms and the risk of acute myocardial infarction. Rev Esp Cardiol 61: 269-275, 2008.
133. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM and Reddy ST: Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. J Biol Chem 276: 44444-44449, 2001. (Pubitemid 37391215)
134. Watson AD, Berlinor JA, Hama SY, La Du BN, Faull KF, Fogelman AM and Navab M: Protective effect of high density lipoprotein associated paraoxonase: inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96: 2882-2891, 1995.
135. Aviram M, Rosenblat M, Bisgaier CL, Newton SL, Primo-Parmo SL and La Du BN: Paroxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest 101: 1581-1590, 1998. (Pubitemid 28198486)
136. Rosenblat M, Gaidukov L, Khersonsky O, Vaya J, Oren R, Tawfik DS: The catalytic histidine dyad of high density lipoprotein-associated serum paraoxonase-1 (PON1) is essential for PON1-mediated inhibition of low density lipoprotein oxidation and stimulation of macrophage cholesterol efflux. J Biol Chem 281: 7657-7665, 2006. (Pubitemid 43847536)
137. La Du BN: Is paraoxonase-3 another HDL-associated protein protective against atherosclerosis? Arterioscler, Thromb Vasc Biol 27: 467-468, 2001.
138. Robertson KS, Hawe E, Miller GJ, Talmud PJ and Humphries SE: Human paraoxonase gene cluster polymorphisms as predictors of coronary heart disease risk in the prospective Northwick Park Heart Study II. Biochim Biophys Acta 1639: 203-212, 2003. (Pubitemid 37421428)
139. Jakubowski H: Calcium-dependent human serum homocysteine thiolactone hydrolase: a protective mechanism against protein N-homocysteinylation. J Biol Chem 275: 3957-3962, 2000.
140. Mackness B, Durrington P, McElduff P, Yarnell J, Azam N, Watt M and Mackness M: Low paraoxonase activity predicts coronary events in the Caerphilly prospective study. Circulation 107: 2775-2779, 2003. (Pubitemid 36705985)
141. Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN and Mackness MI: Paraoxonase status in coronary heart disease are activity and concentration more important than genotype? Arterioscler Thromb Vasc Biol 21: 1451-1457, 2001.
142. Ruiz J, Blanche H, James RW, Garin MCB, Vaisse C, Charpentier G, Cohen N, Morabia A, Passa P and Froguel P: Gln-Arg 192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes. Lancet 346: 869-872, 1995.
143. Odawara M, Tachi Y and Yamashita K: Paraoxonase polymorphism (Glnl92-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 82: 2257-2260, 1997. (Pubitemid 27287594)
144. Sanghera DK, Aston CE, Saha N, Kamboh MI: DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet 62: 36-44, 1998. (Pubitemid 28093832)
145. Ombres D, Pannitteri G, Montali A, Candeloro A, Seccareccia F, Campagna F, Cantini R, Campa PP, Ricci G and Area M: The Gln/Arg192 polymorphism of human paraoxonase gene is not associated with coronary artery disease in Italian patients. Arterioscler Thromb Vasc Biol 18: 1611-1616, 1998. (Pubitemid 28465414)
146. Gardemann A, Philipp M, Heß K, Katz N, Tillmanns H and Haberbosch W: The paraoxonase Leu-Met54 and Gln-Arg191 gene polymorphisms are not associated with the risk of coronary heart disease. Atherosclerosis 152: 421-431, 2000. (Pubitemid 30686331)
147. Nakanishi M, Takanami Y, Maruyama T, Murata M, Motohashi Y, Nakano S, Uchida K, Maruyama C, Kyotani S and Tsushima Motoo: The ratio of serum paraoxonase/arylesterase activity an improved assay for arylesterase activity to discriminate PON1 R192 from PON1 Q192. J Atheroscler Thromb 10: 337-342, 2003.
148. Mackness MI, Arrol S, Mackness B and Durrington PN: Alloenzymes of paraoxonase and effectiveness of high-density lipoprotein in protecting low density lipoprotein against lipid peroxidation. Lancet 349: 851-852, 1997. (Pubitemid 27129220)
149. Jarvik GP, Jampsa R, Richter RJ, Carlson CS, Rieder MJ, Nickerson DA and Furlong CE: Novel paraoxonase (PON1) nonsense and missense mutations predicted by functional genomic assay of PONl status. Pharmacogenetics 13: 291-295, 2003. (Pubitemid 36583997)
150. Mackness B, Mackness MI, Arrol S, Turkie W and Durrington PN: Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Letters 423: 57-60, 1998. (Pubitemid 28098579)
151. Durrington P, Mackness B and Mackness MI: Paraoxonase and atherosclerosis. Arterioscler Thromb Vasc Biol 21: 473-480, 2001.
152. Shih DM, Gu L, Xia YR, Navab M, Hamal S, Castellani LW, Furlong CE, Costa LG, Fogelman AM and Lusis AJ: Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394: 284-287, 1998. (Pubitemid 28335041)
153. Martinelli N, Girelli D, Olivieri O, Stranieri C, Trabetti E, Pizzolo F, Friso S, Tenuti I, Cheng S, Grow MA, Pignatti PF and Corrocher R: Interaction between smoking and PON2 Ser311Cys polymorphism as a determinant of the risk of myocardial infarction. Eur J Clin Invest 34: 14-20, 2004. (Pubitemid 38221734)
154. Chen Q, Reis SE, Kammerer CM, McNamara DM, Holubkov R, Sharaf BL, Sopko G, Pauly DF, Merz CNB, Kamboh MI and the WISE Study Group: Association between the severity of angiographic coronary artery disease and paraoxonase gene polymorphisms in the National Heart, Lung and Blood Institute - sponsored women's ischemia syndrome evaluation (WISE) study. Am J Hum Genet 72: 13-22, 2003. (Pubitemid 36056839)
155. Roy AC, Saha N, Tay JSH and Ratnam SS: Serum paraoxonase polymorphism in three populations of Southeast Asia. Hum Hered 141: 265-269, 1991.
156. Jarvik GP, Rozek LS, Brophy VH, Hatsukami TS, Richter RJ, Schellenberg GD and Furlong CE: Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1 192 or PONl 55 genotype. Arterioscler Thromb Vasc Biol 20: 2441-2447, 2000.
157. Piechota M, Banach M, Jacoń A and Rysz J: Natriuretic peptides in cardiovascular diseases. Cell Mol Biol Lett 13: 155-181, 2008.
158. Vita JA: Endothelial function and clinical outcome (abstract). Heart 91: 1278-1279, 2005. (Pubitemid 41360940)
159. Agapitov AV and Haynes WG: Role of endothelin in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 5: 1-15, 2002.
160. Yanagisawa M, Kurihawa H and Kimura S: A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 332: 411-415, 1988. (Pubitemid 18090241)
161. Hosoda K, Nakao K, Hiroshi-Arai, Suga S, Ogawa Y, Mukoyama M, Shirakami G, Saito Y, Nakanishi S and Imura H: Cloning and expression of human endothelin-1 receptor cDNA. FEBS Lett 287: 23-26, 1991.
162. Ogawa Y, Nakao K and Arai H. Molecular cloning of a nonisopeptide- selective human endothelin receptor. Biochem Biophys Res Commun 178: 248-255, 1991.
163. Spieker LE, Noll G, Ruschitzka FT and Lüscher TF: Endothelin receptor antagonists in congestive heart failure: a new therapeutic principle for the future. J Am Coll Cardiol 37: 1493-1505, 2001.
164. Aydin U, Ugurlucan M, Gungor F, Ziyade S, Inan B, Banach M, Kalko Y and Yasar T: Effects of atorvastatin on vascular intimal hyperplasia: an experimental rodent model. Angiology, 2009.
165. Kohno M, Yokokawa K, Yasunari K, Kano H, Minami M and Yoshikawa J: Effect of the endothelin family of peptides on human coronary artery smooth-muscle cell migration. J Cardiovasc Pharmacol 31: S84-S89, 1998. (Pubitemid 128709877)
166. Jagroop IA, Daskalopoulou SS and Mikhailidis DP: Endothelin-1 and human platelets. Curr Vasc Pharmacol 3: 393-399, 2005.
167. Irzmański R, Banach M, Piechota M, Kowalski J, Barylski M, Cierniewski C and Pawlicki L: Atrial and brain natriuretic peptide and endothelin-1 concentration in patients with idiopathic arterial hypertension: the dependence on the selected morphological parameters. Clin Exp Hypertens 29: 149-164, 2007. (Pubitemid 46744125)
168. Negrusz-Kawecka M: Udział endotelin w schorzeniach układu kra̧żenia. Pol Merk Lek 11: 444-446, 2001.
169. Miyauchi T, Yanagisawa M, Tomizawa T, Sugishita Y, Suzuki N, Fujino M, Ajisaka R, Goto K and Masaki T: Increased plasma concentrations of endothelin-1 and big endothelin-1 in acute myocardial infarction. Lancet 2: 54, 1989. (Pubitemid 19158201)
170. Nessler J, Piwowarska W, Nessler B, Kitliński M, Mroczek-Czernecka D and Stȩpniewski M: Stȩżenie endoteliny 1 (ET-1) u chorych z niewydolnościa̧ serca o etiologii niedokrwiennej. Folia Cardiol 10: 169-175, 2003. (Pubitemid 36857257)
171. Ihara M, Noguchi K, Saeki T, Fukuroda T, Tsuchida S, Kimura S, Fukami T, Ishikawa K, Nishikibe M and Yano M: Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci 50: 247-255, 1992.
172. Tiret L, Poirier O, Hallet V, McDonagh TA, Morrison C, McMuray JJ, Dargie HJ, Arveiler D, Ruidavets JB, Luc G, Evans A and Cambien F: The Lys198Asn polymorphism in the endothelin-1 gene is associated with blood pressure in overweight people. Hypertension 33: 1169-1174, 1999. (Pubitemid 29230968)
173. Iglarz M, Benessiano J, Philip I, Vuillaumier-Barrot S, Lasocki S, Hvass U, Durand G, Desmonts JM, Lévy BI and Henrion D: Preproendothelin-1 gene polymorphism is related to a change in vascular reactivity in the human mammary artery in vitro. Hypertension 39: 209-213, 2002. (Pubitemid 34165216)
174. Asai T, Ohkubo T, Katsuya T, Higaki J, Fu Y, Fukuda M, Hozawa A, Matsubara M, Kitaoka H, Tsuji I, Araki T, Satoh H, Hisamichi S, Imai Y and Ogihara T: Endothelin-1 gene variant associates with blood pressure in obese Japanese subjects: the Ohasama Study. Hypertension 38: 1321-1324, 2001. (Pubitemid 34033410)
175. Colombo MG, Ciofini E, Paradossi U, Bevilacqua S and Biagini A. ET-1 Lys198Asn and ET(A) receptor H323H polymorphisms in heart failure. A case-control study. Cardiology 105: 246-252, 2006.
176. Antoniades C, Tousoulis D, Vasiliadou C, Pitsavos C, Chrysochoou C, Panagiotakos D, Tentolouris C, Marinou K, Koumallos N and Stefanadis C: Genetic polymorphism on endothelial nitric oxide synthase affects endothelial activation and inflammatory response during the acute phase of myocardial infarction. (Abstract). J Am Coll Cardiol 46: 1101-1109, 2005. (Pubitemid 41316521)
177. Ignarro LJ: Physiology and pathophysiology of nitric oxide. Kidney Int (Suppl.) 55: 2-5, 1996.
178. Loscalzo J and Welch G: Nitric oxide and its role in the cardiovascular system. Prog Cardiovasc Dis 38: 87-104, 1995.
179. Schmidt HHHW and Walter U: NO at work. Cell 78: 919-925, 1994.
180. Huang PL, Huang Z and Mashimo H: Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 377: 239-242, 1995.
181. Irokawa M, Nishinaga M, Funayama H and Shimada K: The effect of endothelium-derived relaxing factor (EDRF) on anticoagulant heparan sulfate on cultured vascular endothelial cell (EC). Circulation 90: 1-396, 1994.
182. Morray B, Goldenberg I, Moss AJ, Zareba W, Ryan D, McNitt S, Eberly SW, Glazko G and Mathew J: Polymorphisms in the paraoxonase and endothelial nitric oxide synthase genes and the risk of early-onset myocardial infarction. Am J Cardiol 99: 1100-1105, 2007. (Pubitemid 46560456)
183. Ross R: Atherosclerosis - an inflammatory disease. Nature 340: 115-126, 1999.
184. Schächinger V and Zeiher AM: Atherogenesis-recent insights into basic mechanisms and their clinical impact. Nephrol Dial Transplant 17: 2055-2064, 2002.
185. Cook S: Coronary artery disease, nitric oxide and oxidative stress: the 'Yin-Yang' effect - a Chinese concept for a worldwide pandemic. Swiss Med Wkly 136: 103-113, 2006.
186. Lee CR, North KE, Bray MS, Avery CL, Mosher MJ, Couper DJ, Coresh J, Folsom AR, Boerwinkle E, Heiss G and Zeldin DC: NOS3 polymorphisms, cigarette smoking, and cardiovascular disease risk: The Atherosclerosis Risk in Communities study. Pharmacogenet Genomics 16: 891-899, 2006. (Pubitemid 44772807)
187. Guzik TJ, Black E and West NE: Relationship between the G894T polymorphism (Glu 298Asp variant) in endothelial nitric oxide synthase and nitric oxide mediated endothelial function in human atherosclerosis. Am J Med Genet 100: 130-137, 2001.
188. Naruse K, Shimizu K, Muramatsu M, Toki Y, Miyazaki Y, Okumura K, Hashimoto H and Ito T: Long-term inhibition of NO synthesis promotes atherosclerosis in hypercholesterolemic rabbit thoracic aorta: PGH2 does not contribute to impared endothelium-dependent relaxation. Arterioscler Thromb Vasc Biol 14: 746-752, 1994. (Pubitemid 124004496)
189. Cayatte A, Palacino J, Horten K and Cohen RA: Chronic inhibition of nitric oxide production accelerates neointima formation and impairs endothelial function in hypercholesterolaemic rabbits. Arterioscler Thromb Vasc Biol 14: 753-759, 1994. (Pubitemid 124004497)
190. Cattaruzza M, Guzik TJ, Slodowski W: Shear stress insensitivity of endothelial nitric oxide synthase expression as a genetic risk factor for coronary heart disease. Circ Res 95: 841-847, 2004. (Pubitemid 39390587)
191. Jeerooburkhan N, Jones LC, Bujac S, Cooper JA, Miller GJ, Vallance P, Humphries SE and Hingorani AD: Genetic and environmental determinants of plasma nitrogen oxides and risk of ischemic heart disease. Hypertension 38: 1054-1061, 2001. (Pubitemid 34252805)
192. Hingorani AD, Jia H, Stevens PA, Monteith MS, Brown MJ: A common variant in exon 7 of the endothelial constitutive nitric oxide synthase gene. Clin Sci 88: 21P, 1995.
193. Poirier O, Mao C, Mallet C, Nicaud V, Herrmann S M, Evans A, Ruidavets JB, Arveiler D, Luc G, Tiret L, Soubrier F and Cambien F: Polymorphisms of the endothelial nitric oxide synthase gene: no consistent association with myocardial infarction in ECTIM study. Eur J Clin Invest 29: 284-290, 1999.
194. Bonnardeaux A, Nadaud S, Charru A, Jeunemaitre X, Corvol P and Soubrier F: Lack of evidence for linkage of the endothelial cell nitric oxide synthase gene to essential hypertension. Circulation 91: 96-102, 1995.
195. Rios DL, Callegari-Jacques SM and Hutz MH: Endothelial nitric oxide synthase and fractalkine chemokine receptor polymorphisms on angiographically assessed coronary atherosclerosis. Clin Chim Acta 362: 138-146, 2005.
196. Alvarez R, Gonzales P, Batalla A, Reguero JR, Iglesias-Cubero G, Hevia S, Cortina A, Merino E, González I, Alvarez V and Coto E: Association between the NOS3 (786T/C) and the ACE (I/D) DNA genotypes and early coronary artery disease. Nitric Oxide 5: 343-349, 2001. (Pubitemid 32735386)
197. Miyamoto Y, Yoshihiko S, Kajiyama M, Yoshimura M, Shimasaki Y, Nakayama M, Kamitani S, Harada M, Ishikawa M, Kuwahara K, Ogawa E, Hamanaka I, Takahashi N, Kaneshige T, Teraoka H, Akamizu T, Azuma N, Yoshimasa Y, Yoshimasa T, Itoh H, Masuda I, Yasue H and Nakao K: Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 32: 3-8, 1998. (Pubitemid 28324117)
198. Casas JP, Bautista LE, Humphries SE and Hingorani AD: Endothelial nitric oxide synthase genotype and ischemic heart disease: meta-analysis of 26 studies involving 23,028 subjects. Circulation 109: 1359-1365, 2004.
199. Yoshimura M, Yasue H and Nakayama M: Genetic risk factors for coronary artery spasm: significance of endothelial nitric oxide synthase gene T786C and missense Glu298Asp variants. J Investig Med 48: 367-374, 2000. (Pubitemid 30677272)
200. Gomma AH, Elrayess MA, Knight CJ, Hawe E, Fox KM and Humphries SE: The endothelial nitric oxide synthase (Glu298Asp and 786T/C) gene polymorphisms are associated with coronary in-stent restenosis. Eur Heart J 23: 1955-1962, 2002.
201. Tesauro M, Thompson WC, Rogliani P, Qi L, Chaudhary PP and Moss J: Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. Proc Natl Acad Sci USA 97: 2832-2835, 2000. (Pubitemid 30159257)
202. McDonald DM, Alp NJ and Channon KM: Functional comparison of the endothelial nitric oxide synthase Glu298Asp polymorphic variants in human endothelial cells. Pharmacogenetics 14: 831-839, 2004. (Pubitemid 40054338)
203. Fairchild TA, Fulton D, Fontana JT, Gratton JP, McCabe TJ and Sessa WC: Acidic hydrolysis as a mechanism for the cleavage of the Glu(298)Asp variant of human endothelial nitric oxide synthase. J Biol Chem 276: 26674-26679, 2001. (Pubitemid 37412891)
204. Joshi MS, Mineo C, Shaul PW and Bauer JA: Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: altered caveolar localization and impaired response to shear. FASEB J 21: 2655-2663, 2007. (Pubitemid 47372733)
205. Busconi L and Michel T: Endothelial nitric oxide synthase. N-terminal myristoylation determines subcellular localization. J Biol Chem 268: 8410-8413, 1993. (Pubitemid 23118614)
206. Agema WR, De Maat MP, Zwinderman AH, Kastelein JJ, Rabelink TJ, Van Boven AJ, Feskens EJ, Boer JM, van der Wall EE and Jukema JW: An integrated evaluation of endothelial constitutive nitric oxide synthase polymorphisms and coronary artery disease in men. Clin Sci 107: 255-261, 2004.
207. Lembo G, De Luca N, Battagli C, Iovino G, Aretini A, Musicco M, Frati G, Pompeo F, Vecchione C and Trimarco B: A Common variant of endothelial nitric oxide synthase (Glu298Asp) is an independent risk factor for carotid atherosclerosis. Stroke 32: 735-740, 2001. (Pubitemid 32208729)
208. Nakayama M, Yasue H and Yoshimura M: T-786C mutation in the 5′-flanking region of the enothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 99: 2864-2870, 1999. (Pubitemid 29258973)
209. Miyamoto Y, Saito Y and Nakayama M: Replication protein A1 reduces transcription of the endothelial nitric oxide synthase gene containing a -786T/C mutation associated with coronary spastic angina. Hum Mol Genet 9: 2629-2637, 2000. (Pubitemid 30838164)
210. Rossi GP, Cesari M, Zanchetta M, Colonna S, Maiolino G, Pedon L, Cavallin M, Maiolino P and Pessina AC: The T-786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study. J Am Coll Cardiol 41: 930-937, 2003. (Pubitemid 36315532)
211. Rossi GP, Taddei S, Virdis A, Cavallin M, Ghiadoni L, Favilla S, Versari D, Sudano I, Pessina AC and Salvetti A: The T-786C and Glu298Asp polymorphisms of the endothelial nitric oxide gene affect the forearm blood flow responses of Caucasian hypertensive patients. J Am Coll Cardiol 41: 938-948, 2003. (Pubitemid 36315533)
212. Colombo MG, Andreassi MG, Botto N, Manfredi S, Masetti S, Biagini A and Clerico A: Endothelial nitric oxide synthase gene polymorphisms and risk of coronary artery disease. Clin Chem 49: 389-395, 2003. (Pubitemid 36250199)
213. Yoon Y, Song J, Hong SH and Kim JQ: Plasma nitric oxide concentrations and nitric oxide synthase gene polymorphisms in coronary artery disease. Clin Chem 46: 1626-1630, 2000. (Pubitemid 30776628)
214. Derebecka N, Hołysz M, Dankowski R, Wierzchowiecki M and Trzeciak WH: Polymorphism in intron 23 of the endothelial nitric oxide synthase gene (NOS3) is not associated with hypertension. Acta Biochimica Polonica 49: 263-268, 2008.
215. Nap A, Balt JC, Mathy MJ and van Zwieten PA: AT1-receptor blockade and sympathetic neurotransmission in cardiovascular disease. Autonomic Autacoid Pharmacol 23: 285-296, 2004.
216. Bristow MR: Beta-adrenergic receptor blockade in chronic heart failure. Circulation 101: 558-569, 2000. (Pubitemid 30080872)
217. Francis GS, McDonald KM and Cohn JN: Neurohumoral activation in preclinical heart failure. Remodeling and the potential for intervention. Circulation 87 suppl 5: IV-90-IV-96, 1993.
218. Communal C, Sigh K, Pimental DR and Colucci WS: Norepinephrine stimulates apoptosis in adult rat ventricular myocytes by activation of the β-adrenergic receptor. Circulation 98: 1329-1334, 1998. (Pubitemid 28443398)
219. Kozłowska H, Schlicker E, Kozłowski M, Siedlecka U, Laudański J and Malinowska B: Ligands at β2-, β3- and the low-affinity state of β1-adrenoceptors block the α1 adrenoceptor-mediated constriction in human pulmonary and rat mesenteric arteries. J Cardiovasc Pharmacol 46: 76-82, 2005.
220. White HL, Maqbool A, McMahon AD, Yates L, Ball SG, Hall AS and Balmorth AJ: An evaluation of the β1 adrenergic receptor Arg389Gly polymorphism in individuals at risk of coronary events. A WOSCOPS substudy. Eur Heart J 23: 1087-1092, 2002. (Pubitemid 35230713)
221. Metra M, Nodari S, D'Aloia A, Bontempi L, Boldi E and Cas LD: A rationale for the use of beta-blockers as standard treatment for heart failure. Am Heart J 139: 511-521, 2000. (Pubitemid 30149202)
222. Böhm M, Flesch M and Schnabel P: Beta-adrenergic signal transduction in the failing and hypertrophied myocardium. J Mol Med 75: 842-848, 1997. (Pubitemid 27511560)
223. Lefkowitz RJ, Rockman HA and Koch WJ: Catecholamines, cardiac β adrenergic receptors, and heart failure. Circulation 101: 1634-1637, 2000. (Pubitemid 30196619)
224. Eichhorn EJ and Bristow MR: Medical therapy can improve the biological properties of the chronically failing heart: a new era in the treatment of heart failure. Circulation 94: 2285-2296, 1996.
225. Biolol A, Rosal AS, Mazzottil NG, Martins S, Belló-Klein A, Rohde LE and Clausell N: The role of adrenergic receptor polymorphisms in heart failure. Braz J Med Biol Res 39: 1281-1290, 2006. (Pubitemid 46370330)
226. Mialet PJ, Rathz DA, Petrashevskaya NN, Hahn HS, Wagoner LE, Schwartz A, Dorn GW and Liggett SB: β1 Adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nat Med 9: 1300-1305, 2003. (Pubitemid 37279854)
227. Small KM, Wagoner LE, Levin AM, Kardia SLR and Liggett SB: Synergistic polymorphisms of β1 and α2C adrenergic receptors and the risk of congestive heart failure. N Engl J Med 347: 1135-1142, 2002.
228. Brodde OE, Buscher R, Tellkamp R, Radke J, Dhein S and Insel PA: Blunted cardiac responses to receptor activation in subjects with Thr164Ile β2-adrenoreceptors. Circulation 103: 1048-1050, 2001. (Pubitemid 32200175)
229. Green SA, Cole G, Jacinto M, Innis M and Liggett SB: A polymorphism of the human β2 adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 268: 23116-23121, 1993. (Pubitemid 23328021)
230. Turki J, Lorenz JN, Green SA, Donnelly ET, Jacinto M and Liggett SB: Myocardial signaling defects and impaired cardiac function of a human β2 adrenergic receptor polymorphism expressed in transgenic mice. Proc Natl Acad Sci USA 93: 10483-10488, 1996. (Pubitemid 26314649)
231. Liggett SB, Wagoner LE, Craft LL, Hornung RW, Hoit BD, Mcintosh TC and Walsh RA: The Ile 164 β2 adrenergic receptor polymorphism adversely affects the outcome of congestive heart failure. J Clin Invest 102: 1534-1539, 1998.
232. Parker JD, Newton GE, Landzberg JS, Floras JS and Colucci WS: Functional significance of presynaptic α adrenergic receptors in failing and nonfailing human left ventricle. Circulation 92: 1793 - 1800, 1995.
233. Small KM, Forbes SL, Rahman FF, Bridges KM and Liggett SB: A four amino acid deletion polymorphism in the third intracellular loop of the human α2C adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 275: 23059-23064, 2000.